Abstract Body

Background

Dolutegravir (DTG) and other integrase inhibitors have been associated with an increased risk of hypertension (HTN); however, the data are conflicting and limited from low- and middle-income countries (LMICs). The weight gain threshold associated with HTN risk is also unclear, with prior studies using increases of ≥5% or ≥10%. We evaluated the association between weight gain and incident HTN among people living with HIV (PLWH) switched to DTG between 2017 and 2023 at the Infectious Diseases Institute in Kampala, Uganda.

Methods

We studied PLWH without HTN who had been on ART for at least 24 months before the switch to DTG. We determined the incidence of HTN (2 sequential measures of systolic blood pressure (SBP) ≥ 140 mm Hg, Diastolic blood pressure (DBP) ≥ 90 mm Hg, or initiation of anti-HTN treatment, or a clinical diagnosis) in the period 24 months before (pre-DTG period), and 24 months after switching (DTG period). We compared incidence rates of HTN in the two time periods using Cox proportional models adjusted for baseline age, sex, duration on ART, WHO stage at ART start, previous use of stavudine and zidovudine, and diabetes. In sensitivity analyses, we also compared the risk of incident HTN with a ≥5% and ≥ 10% weight increase in the DTG period.

Results

We studied 4982 PLWH whose median age was 43 (Interquartile range IQR: 37-49) years, 61% were female, with a median ART duration of 8.5 years (IQR: 5.9-12.4) and median BMI of 23.7 kg/m2 (IQR: 20.9-27.4). We found 130 (2.6%) PLWH with incident HTN in the pre-DTG period (incidence rate IR 14.4 /1000-person years) and 358 (7.4%) in the DTG period (IR 28.3/1000-person years). In the adjusted model not controlling for body mass index (BMI), the hazard ratio (aHR) for HTN in the DTG vs pre-DTG period was 1.3 (95% Confidence Interval CI: 1.1-1.7, p=0.012). The HR remained significant after controlling for time-updated log BMI (aHR 1.3, 95% CI: 1.0-1.6, p=0.033). However, the risk in HTN was mainly driven by an increase in time-updated log BMI (aHR 2.1, CI: 1.3-3.4, p=0.001) and age≥45 years (aHR 1.8, 95% CI: 1.3-2.5, p<0.001). Both a 5-<10% (aHR 1.7, 95% CI: 1.2-2.2, p=<0.001) and a ≥ 10% increase in weight (aHR 1.8, 95% CI: 1.3-2.5, p=<0.001) were associated with an increased risk of HTN compared to ≤0 % in the DTG period.

Conclusions

DTG use was associated with increased HTN risk, largely explained by weight gain. Lifestyle modification and HTN management should be integrated into HIV programs in LMICs.